Sugi Predict

Sugi Predict / Compounds / SCHEMBL204668

SCHEMBL204668

SCHEMBL204668

COC(=O)c1cccc(N)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.69
▸ HSD17B10 Q99714 4/20 0.69
▸ CFTR P13569 1/20 0.69
▸ MMP2 P08253 1/20 0.60
▸ TSHR P16473 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ KDM4E B2RXH2 7/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ GAA P10253 5/20 0.49
▸ MAPT P10636 4/20 0.49
▸ HPGD P15428 3/20 0.49
▸ GLA P06280 2/20 0.49
▸ ATM Q13315 2/20 0.49
▸ CASP1 P29466 1/20 0.49
▸ CASP7 P55210 1/20 0.49
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA7 P43166 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31258869 1.00 ALDH1A1 (0.69) ALDH1A1HSD17B10CFTRMMP2TSHR
Hydrochloric Acid SCHEMBL27547428 0.98 ALDH1A1 (0.67) ALDH1A1HSD17B10CFTRMMP2TSHR
SCHEMBL1538293 0.86 TSHR (0.65) ALDH1A1HSD17B10CFTRTSHRLMNA
SCHEMBL31589985 0.82 ALDH1A1 (0.71) ALDH1A1HSD17B10CFTRTSHRLMNA
SCHEMBL19169375 0.82 MMP2 (0.62) ALDH1A1HSD17B10CFTRMMP2TSHR
SCHEMBL505249 0.82 ALDH1A1 (0.71) ALDH1A1HSD17B10CFTRTSHRLMNA
Methyl Anthranilate SCHEMBL901249 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10CFTRTSHRLMNA
Methyl Anthranilate SCHEMBL29444250 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10CFTRTSHRLMNA
Methyl Anthranilate SCHEMBL57713 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10CFTRTSHRLMNA
Methyl Anthranilate SCHEMBL29564148 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10CFTRTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116730657-B Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2024-07-12 — — CN claimed
CN-116730657-A Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2023-09-12 — — CN claimed
CN-113862702-A Synthesis method for preparing phenoxazinone compound by electrochemically oxidizing o-aminophenol analog 温州医科大学 2021-12-31 — — CN claimed
WO-2003016615-A1 SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES NOVOZYMES NORTH AMERICA, INC. (US) 2003-02-27 — — WO claimed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 — — US disclosed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 — — US disclosed
CN-121574765-A Lubricating grease composition for roller bearing and preparation method thereof 廊坊市兰春润滑脂有限公司 2026-02-27 — — CN disclosed
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF NEWAVE PHARMACEUTICAL INC. 2025-03-06 — — US disclosed
CN-112996786-B Compounds for inhibiting alpha 4 beta 7 integrin 吉利德科学公司 2024-08-20 — — CN disclosed
CN-116730657-B Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2024-07-12 — — CN disclosed
CN-115260180-B Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2024-05-28 — — CN disclosed
US-20240165131-A1 TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS THE CLEVELAND CLINIC FOUNDATION 2024-05-23 — — US disclosed
WO-1995028397-A1 ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-10-26 — — WO disclosed
US-5412099-A Intermediate benzothiazolyl- and benzoxazolyl-aldehyde compounds BAYER AKTIENGESELLSCHAFT (DE) 1995-05-02 — — US disclosed
US-5254692-A Inotropic BAYER AKTIENGESELLSCHAFT (DE) 1993-10-19 — — US disclosed
US-5200420-A Inotropic agents for cardiovascular disorders BAYER AKTIENGESELLSCHAFT (DE) 1993-04-06 — — US disclosed
US-4233055-A Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents CIBA-GEIGY CORPORATION (US) 1980-11-11 — — US disclosed
US-4141718-A ANTIGROWTH AGENTS FOR PLANTS CIBA-GEIGY CORPORATION (US) 1979-02-27 — — US disclosed
US-4110246-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DE) 1978-08-29 — — US disclosed
US-4036951-A SUNSCREEN AGENTS SYNERGISTICS, INC. (US) 1977-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels BHMT, BHMT2, EHMT2 ALDH1A1 1296/4885HSD17B10 2588/4885CFTR 686/4885
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF FOXM1, MDM2, FOXO1 ALDH1A1 620/4885HSD17B10 3512/4885CFTR 1314/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP ALDH1A1 1320/4885HSD17B10 2871/4885CFTR 1436/4885
US-20240165131-A1 TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS MAOB, DAO, ESD ALDH1A1 239/4885HSD17B10 402/4885CFTR 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.